Clinical Trial

AlloSure Lung Assessment and Metagenomics Outcomes Study

Study acronym: ALAMO
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
ALAMO is a prospective, multi-center, perspective, registry of patients receiving LungCare™ (AlloSure®-Lung, AlloMap Lung, and HistoMap) for surveillance post-transplant. This study aims to evaluate the diagnostic performance characteristics of AlloSure Lung (dd-cfDNA) to detect a spectrum of rejection (ACR, AMR) and allograft infection (Bacterial, Viral, Fungal, Mycobacterial, Parasitic).
Protocol Amendment History 23 amendments
This ClinicalTrials.gov record has been amended 23 times since 2021-09-17; most recent amendment 2026-06-23.
Status change: Recruiting → Active, Not Recruiting 2025-10-16
Status change: Not Yet Recruiting → Recruiting 2021-11-03
Trial Details
NCT Number NCT05050955
Lead Sponsor CareDx
Conditions Lung Transplant Infection, Lung Transplant; Complications, Lung Transplant Failure and Rejection
Enrollment 550 participants
Start Date 2021-10-29
Primary Completion 2028-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-25